Evaluation of olanzapine for breakthrough emesis in patients with cancer not responding to standard antiemetic regimen.

Authors
Publication date
Publisher
'American Society of Clinical Oncology (ASCO)'
Doi

    Abstract

    Abstract is not available.

      Similar works

      Full text

      thumbnail-image

      Available Versions

      Crossref

      redirect
      oaiinfo:doi/10.1200%2Fjco.2011.29...
      Last time updated on 25/10/2020